3 of the best ASX 200 shares to buy now with $5,000

Investors with money to invest might want to check out these shares that analysts rate as buys.

| More on:
Three happy office workers cheer as they read about good financial news on a laptop.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Do you have $5,000 ready to invest? Whether you're topping up your portfolio or getting started on your ASX journey, choosing the right shares now could make a meaningful difference over the long term.

In today's uncertain market, quality matters. That means focusing on companies with strong fundamentals, durable earnings, and the ability to grow through cycles.

With that in mind, here are three of the best ASX 200 shares to consider buying right now according to analysts — each offering something a little different, but all built for long-term success. They are as follows:

CSL Ltd (ASX: CSL)

CSL is one of the Australian share market's most iconic companies — and for good reason. This biotech giant develops life-saving therapies across immunology, vaccines, and rare diseases.

The company already has a world class product portfolio, but this doesn't stop it from investing US$1 billion+ into R&D activities each year. This ensures that the company is at the forefront of the industry and has a pipeline of potentially lucrative products to drive its future growth.

Analysts are feeling very positive about the company's outlook and are forecasting double-digit earnings growth in the coming years thanks to the key CSL Behring plasma business.

Bell Potter feels that its shares are cheap based on this growth outlook. As a result, it has put a buy rating and $335.00 price target on its shares.

Pro Medicus Ltd (ASX: PME)

Another ASX 200 share to buy with the $5,000 is Pro Medicus. It is a high-margin, founder-led business that provides advanced imaging software to some of the world's leading hospitals. Its Visage platform helps radiologists analyse medical images faster and more efficiently — a critical need in modern healthcare.

Backed by long-term contracts, Pro Medicus generates strong recurring revenue, incredible operating margins, and returns on capital most companies can only dream of.

And while it trades at a premium, this is arguably justified given its quality and long term growth potential.

Goldman Sachs sees plenty of upside for investors. The broker has put a buy rating and $309.00 price target on its shares.

Woolworths Group Ltd (ASX: WOW)

Finally, Woolworths could be an ASX 200 share to buy according to analysts.

When markets get rocky, Woolworths is the kind of business investors tend to lean on. With a dominant position in Australian supermarkets, a strong loyalty program, and reliable cash flow, it offers defensive stability with modest growth.

While it may not deliver the same excitement as a tech stock, its steady dividends, strong market position and brand loyalty make it a great anchor for any portfolio.

Goldman Sachs is also bullish on this one. It has a buy rating and $36.50 price target on its shares.

Motley Fool contributor James Mickleboro has positions in CSL and Pro Medicus. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Goldman Sachs Group. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended CSL and Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Blue Chip Shares

man in old fashioned suit and hat looking through magnifying glass
Blue Chip Shares

Is the CSL share price a generational bargain at $180?

CSL shares are currently trading near a 7-year low.

Read more »

Machinery at a mine site.
Blue Chip Shares

BHP signs US$2 billion deal: Here's the key takeaway

Let’s take a look at what was announced.

Read more »

Business people discussing project on digital tablet.
Blue Chip Shares

Buy, hold, sell: Medibank, Qantas, and Xero shares

Let's see what analysts are saying about these popular blue chip shares.

Read more »

Man holding out $50 and $100 notes in his hands, symbolising ex dividend.
Blue Chip Shares

2 ASX blue-chip shares offering big dividend yields

Defensive businesses with big yields could be strong choices today…

Read more »

A financial expert or broker looks worried as he checks out a graph showing market volatility.
Blue Chip Shares

2 big ASX 200 shares this fund manager rates as buys

These large businesses could be strong contenders for returns.

Read more »

A fit woman in workout gear flexes her muscles with two bigger people flexing behind her, indicating growth.
Blue Chip Shares

3 ASX blue-chip shares I'd buy with $3,000 right now

These big stocks have a strong market position. Here’s why they’re buys…

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Blue Chip Shares

3 high-quality ASX 200 shares now trading at multi-year discounts

These shares could be dirt cheap according to analysts.

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Blue Chip Shares

Where to invest $10,000 in ASX shares in December

These shares could be great picks for Aussie investors this month.

Read more »